PharmaSGP Holding SE

XETRA PSG.DE

PharmaSGP Holding SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -19.48 M

PharmaSGP Holding SE Net Cash Used Provided By Financing Activities is USD -19.48 M for the year ending December 31, 2023, a -50.37% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • PharmaSGP Holding SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -12.95 M, a -113.54% change year over year.
  • PharmaSGP Holding SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 95.67 M, a 182.41% change year over year.
  • PharmaSGP Holding SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD -116.09 M, a -1,671.66% change year over year.
  • PharmaSGP Holding SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD -6.55 M, a -33.09% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
XETRA: PSG.DE

PharmaSGP Holding SE

CEO Ms. Natalie Weigand
IPO Date June 19, 2020
Location Germany
Headquarters Lochhamer Schlag 21
Employees 89
Sector Health Care
Industries
Description

PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.

Similar companies

SBS.DE

Stratec SE

USD 29.11

3.16%

AJ91.DE

DocCheck AG

USD 9.64

1.15%

OHB.DE

OHB SE

USD 49.68

-0.22%

DMP.DE

Dermapharm Holding SE

USD 41.22

0.60%

M7U.DE

Nynomic AG

USD 21.54

1.09%

StockViz Staff

January 15, 2025

Any question? Send us an email